Acadia Pharmaceuticals
ACAD Mid CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Acadia Pharmaceuticals en bref
Acadia Pharmaceuticals (ACAD) is currently trading at 22,46 € with a market capitalization of 3,8 Md €. The trailing P/E ratio stands at 11.71x, with a forward P/E of 30.27x. The 52-week range spans from 17,10 € to 24,62 €; the current price is 8.7% below the yearly high. Year-over-year revenue growth stands at +9.7%. The net profit margin stands at 34.3%.
💰 Dividende
Acadia Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
20 analystes évaluent Acadia Pharmaceuticals (ACAD) au consensus : Acheter. L'objectif de cours moyen est de 28,61 €, soit un potentiel de +27.37% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 14,76 € à 39,07 €.
Acadia Pharmaceuticals : la thèse d'investissement en détail
Acadia Pharmaceuticals (ACAD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 61.58%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 37.32% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 34.3%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
Le scénario baissier
Short interest sits at 10.22% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
At a PEG of 50.86, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 39.15x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The analyst consensus price target implies 27.37% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentable avec une marge nette de 34.3%
- Rentabilité élevée des capitaux propres (37.32% ROE)
- Marge brute élevée de 61.58% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Actuellement jugée sous-évaluée
- Bilan solide avec faible endettement (D/E 4.07)
- Free cash flow positif
- –Positions vendeuses élevées (10.22%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (10.22%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Acadia Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news